Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9564 |
IRE1α kinase-IN-1
|
IRE1 | Cell Cycle/Checkpoint |
IRE1α kinase-IN-1 是IRE1α 的选择性抑制剂(IC50为 77 nM),对 IRE1α 的选择性高于 IRE1β 亚型 100 倍。它抑制内质网诱导的 IRE1α 寡聚和自磷酸化,并抑制 IRE1α RNase 活性 (IC50=80 nM)。 | |||
T11669 |
IR415
|
HBV | Microbiology/Virology |
IR415 选择性地与 HBx 相互作用 (Kd=2 nM) 并阻断 HBV 介导的 RNAi 抑制,逆转 HBx 蛋白对 Dicer 核糖核酸内切酶活性的抑制作用。IR415 具有抗 HBV 的活性。 | |||
T63951 | ZINC000104379474 | ||
ZINC000104379474 是靶向 SARS-CoV-2 内切核糖核酸酶的化合物。 | |||
T24098 |
GP17
GP-17,GP 17 |
||
GP17 is a type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α. | |||
T24099 |
GP29
GP-29,GP 29 |
||
GP29 is a Type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α. | |||
T38234 | HCoV-229E-IN-1 | ||
HCoV-229E-IN-1 is a potent inhibitor of HCoV-229E replication, with an EC50 of 0.65 μM and 0.6 μM in MTS and CPE cells, respectively[1]. HCoV-229E-IN-1 (compound 5h) (0.01-100 μM) fully suppresses the capacity of HCoV-229E replication in a dose-dependent manner[1].HCoV-229E-IN-1 (12 μM) fully prevented the formation of dsRNA intermediates of CoV RNA synthesis[1]. [1]. Stevaert A, et, al. Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease... |